Q1 Earnings Forecast for Teleflex Issued By Citizens Jmp

Teleflex Incorporated (NYSE:TFX - Free Report) - Analysts at Citizens Jmp issued their Q1 2025 earnings estimates for shares of Teleflex in a research note issued on Wednesday, April 2nd. Citizens Jmp analyst D. Turkaly forecasts that the medical technology company will post earnings per share of $2.77 for the quarter. Citizens Jmp currently has a "Market Perform" rating on the stock. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Citizens Jmp also issued estimates for Teleflex's Q2 2025 earnings at $3.45 EPS, Q3 2025 earnings at $3.70 EPS, Q4 2025 earnings at $4.18 EPS, FY2025 earnings at $14.10 EPS, Q1 2026 earnings at $3.47 EPS, Q2 2026 earnings at $3.80 EPS, Q3 2026 earnings at $3.88 EPS, Q4 2026 earnings at $4.10 EPS and FY2026 earnings at $15.25 EPS.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.86 by $0.03. The company had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. Teleflex had a net margin of 7.85% and a return on equity of 14.19%.

Several other research firms also recently issued reports on TFX. Bank of America downgraded Teleflex from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $235.00 to $140.00 in a research note on Tuesday, March 4th. StockNews.com cut shares of Teleflex from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Morgan Stanley lowered their price target on shares of Teleflex from $275.00 to $191.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Raymond James downgraded Teleflex from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada lowered Teleflex from an "outperform" rating to a "sector perform" rating and reduced their target price for the company from $220.00 to $155.00 in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $181.50.

Remove Ads

Teleflex Price Performance

TFX stock traded up $0.74 during midday trading on Monday, hitting $129.81. 642,249 shares of the stock were exchanged, compared to its average volume of 614,950. The stock's 50-day moving average price is $148.00 and its 200-day moving average price is $181.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The stock has a market cap of $6.02 billion, a price-to-earnings ratio of 25.81, a PEG ratio of 1.73 and a beta of 1.19. Teleflex has a fifty-two week low of $124.66 and a fifty-two week high of $249.91.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new position in Teleflex in the fourth quarter valued at $29,000. MassMutual Private Wealth & Trust FSB boosted its stake in Teleflex by 103.1% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock worth $27,000 after buying an additional 100 shares during the last quarter. Whipplewood Advisors LLC grew its holdings in Teleflex by 7,700.0% in the 1st quarter. Whipplewood Advisors LLC now owns 234 shares of the medical technology company's stock valued at $32,000 after buying an additional 231 shares during the period. True Wealth Design LLC increased its stake in shares of Teleflex by 62.3% during the 4th quarter. True Wealth Design LLC now owns 271 shares of the medical technology company's stock valued at $48,000 after acquiring an additional 104 shares during the last quarter. Finally, Avior Wealth Management LLC lifted its holdings in shares of Teleflex by 81.2% during the 4th quarter. Avior Wealth Management LLC now owns 279 shares of the medical technology company's stock worth $50,000 after acquiring an additional 125 shares during the period. Hedge funds and other institutional investors own 95.62% of the company's stock.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 17th. Shareholders of record on Friday, March 7th were paid a $0.34 dividend. The ex-dividend date of this dividend was Friday, March 7th. This represents a $1.36 annualized dividend and a yield of 1.05%. Teleflex's payout ratio is currently 95.77%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.